Cipla Ltd
Cipla is engaged in the Business of Pharmaceuticals.(Source : 202003 Annual Report Page No:157)
- Market Cap ₹ 77,959 Cr.
- Current Price ₹ 966
- High / Low ₹ 1,185 / 852
- Stock P/E 26.6
- Book Value ₹ 290
- Dividend Yield 0.88 %
- ROCE 18.8 %
- ROE 13.2 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 19.1%
Cons
- The company has delivered a poor sales growth of 8.47% over past five years.
- Company has a low return on equity of 13.4% over last 3 years.
- Promoter holding has decreased over last 3 years: -3.13%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
7,021 | 8,279 | 10,173 | 11,345 | 13,790 | 14,394 | 15,156 | 16,362 | 17,132 | 19,160 | 21,763 | 22,753 | |
5,325 | 6,065 | 8,026 | 9,183 | 11,310 | 11,898 | 12,329 | 13,265 | 13,926 | 14,907 | 17,211 | 17,726 | |
Operating Profit | 1,696 | 2,214 | 2,147 | 2,163 | 2,480 | 2,496 | 2,826 | 3,097 | 3,206 | 4,252 | 4,553 | 5,027 |
OPM % | 24% | 27% | 21% | 19% | 18% | 17% | 19% | 19% | 19% | 22% | 21% | 22% |
103 | 245 | 251 | 164 | 208 | 208 | 280 | 477 | 344 | 266 | 99 | 293 | |
Interest | 38 | 34 | 146 | 168 | 207 | 159 | 114 | 168 | 197 | 161 | 106 | 110 |
Depreciation | 312 | 330 | 373 | 505 | 754 | 1,323 | 1,323 | 1,326 | 1,175 | 1,068 | 1,052 | 1,172 |
Profit before tax | 1,448 | 2,095 | 1,880 | 1,654 | 1,727 | 1,222 | 1,669 | 2,079 | 2,178 | 3,290 | 3,493 | 4,038 |
Tax % | 21% | 26% | 25% | 24% | 19% | 15% | 15% | 27% | 29% | 27% | 27% | 30% |
Net Profit | 1,144 | 1,545 | 1,404 | 1,229 | 1,383 | 1,035 | 1,417 | 1,492 | 1,500 | 2,389 | 2,547 | 2,833 |
EPS in Rs | 14.25 | 19.24 | 17.29 | 14.71 | 16.93 | 12.51 | 17.52 | 18.96 | 19.18 | 29.82 | 31.19 | 34.71 |
Dividend Payout % | 14% | 10% | 12% | 14% | 12% | 16% | 17% | 16% | 21% | 17% | 16% | 24% |
Compounded Sales Growth | |
---|---|
10 Years: | 11% |
5 Years: | 8% |
3 Years: | 10% |
TTM: | 5% |
Compounded Profit Growth | |
---|---|
10 Years: | 7% |
5 Years: | 17% |
3 Years: | 28% |
TTM: | 13% |
Stock Price CAGR | |
---|---|
10 Years: | 10% |
5 Years: | 12% |
3 Years: | 14% |
1 Year: | 1% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 12% |
3 Years: | 13% |
Last Year: | 13% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | |
Reserves | 7,478 | 8,858 | 9,890 | 10,641 | 11,356 | 12,383 | 14,068 | 14,851 | 15,602 | 18,165 | 20,680 | 23,246 |
29 | 967 | 1,248 | 1,703 | 5,202 | 4,113 | 4,098 | 4,316 | 2,816 | 2,014 | 1,056 | 803 | |
1,682 | 1,672 | 2,102 | 3,166 | 4,331 | 4,213 | 4,346 | 4,433 | 4,843 | 4,514 | 4,960 | 5,252 | |
Total Liabilities | 9,350 | 11,658 | 13,400 | 15,670 | 21,049 | 20,869 | 22,673 | 23,762 | 23,423 | 24,855 | 26,857 | 29,463 |
3,215 | 3,610 | 6,496 | 6,830 | 9,368 | 9,492 | 9,950 | 9,608 | 9,683 | 9,516 | 9,683 | 9,565 | |
CWIP | 371 | 378 | 442 | 581 | 2,061 | 1,683 | 981 | 676 | 825 | 969 | 766 | 689 |
Investments | 1,269 | 2,532 | 709 | 640 | 759 | 973 | 1,259 | 2,554 | 1,471 | 2,710 | 2,551 | 3,662 |
4,494 | 5,138 | 5,753 | 7,620 | 8,862 | 8,721 | 10,483 | 10,923 | 11,444 | 11,661 | 13,857 | 15,547 | |
Total Assets | 9,350 | 11,658 | 13,400 | 15,670 | 21,049 | 20,869 | 22,673 | 23,762 | 23,423 | 24,855 | 26,857 | 29,463 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,713 | 1,398 | 1,563 | 1,173 | 1,741 | 2,382 | 1,463 | 1,691 | 3,068 | 3,755 | 3,326 | 3,238 | |
-965 | -2,063 | -1,265 | -950 | -4,533 | -1,304 | -834 | -1,688 | 114 | -2,374 | -1,858 | -2,389 | |
-753 | 718 | -266 | 165 | 3,104 | -1,326 | -385 | -349 | -2,949 | -1,240 | -1,600 | -958 | |
Net Cash Flow | -6 | 53 | 33 | 388 | 312 | -248 | 243 | -345 | 234 | 141 | -132 | -109 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 81 | 74 | 59 | 64 | 62 | 65 | 75 | 93 | 83 | 66 | 57 | 65 |
Inventory Days | 247 | 295 | 273 | 329 | 273 | 239 | 271 | 250 | 267 | 232 | 230 | 228 |
Days Payable | 92 | 102 | 92 | 126 | 106 | 108 | 142 | 123 | 139 | 103 | 108 | 109 |
Cash Conversion Cycle | 235 | 266 | 239 | 267 | 230 | 196 | 204 | 220 | 211 | 195 | 180 | 184 |
Working Capital Days | 136 | 142 | 126 | 133 | 121 | 111 | 129 | 143 | 122 | 106 | 104 | 173 |
ROCE % | 20% | 24% | 19% | 15% | 13% | 7% | 10% | 11% | 12% | 17% | 18% | 19% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Updates on Acquisition
31 May - The proposed sale of stake held in Cipla Quality Chemical Industries Limited(CQCIL), step-down subsidiary of the Company in Uganda, is expected to be completed on …
- Compliances-Reg.24(A)-Annual Secretarial Compliance 30 May
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 29 May
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
26 May - The Operations and Administrative Committee of the Company on 26th May 2023 has allotted 67,306 fully paid-up equity shares of INR 2 each, pursuant to …
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
16 May - Copy of the transcript of the Company's Q4 FY23 earnings conference call dated 12th May 2023. The transcript is also available on the Company's website …
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
May 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jul 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Oct 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021TranscriptPPT
-
May 2021TranscriptPPT
-
May 2021Transcript PPT
-
Feb 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Jan 2021Transcript PPT
-
Nov 2020TranscriptPPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptPPT
-
Aug 2020Transcript PPT
-
May 2020TranscriptPPT
-
May 2020Transcript PPT
-
Feb 2020TranscriptPPT
-
Feb 2020Transcript PPT
-
Nov 2019TranscriptPPT
-
Nov 2019Transcript PPT
-
Aug 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
Jun 2019TranscriptPPT
-
May 2019Transcript PPT
-
May 2019TranscriptNotesPPT
-
Feb 2019TranscriptPPT
-
Feb 2019Transcript PPT
-
Nov 2018TranscriptPPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018TranscriptNotesPPT
-
Feb 2018Transcript PPT
-
Feb 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
-
Aug 2017TranscriptNotesPPT
-
May 2017TranscriptNotesPPT
-
May 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
-
Nov 2016TranscriptNotesPPT
-
Aug 2016TranscriptNotesPPT
-
May 2016TranscriptNotesPPT
-
Nov 2015TranscriptNotesPPT
-
Aug 2015TranscriptNotesPPT
Market Leadership
Cipla is the 3rd largest pharmaceutical player in India and leader in therapies such as respiratory and urology. It also ranks 2nd in the overall chronic business. It continues to be the 3 rd largest player in the South African private market with 7.5% market share, growing ~4.3% greater than market. [1] It is the 2nd largest Indian exporter in emerging markets. [2]